West Pharmaceutical Services (WST) Other Non-Current Assets (2009 - 2026)

West Pharmaceutical Services has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $81.3 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $81.3 million, up 15.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.3 million (up 15.81% YoY), and the FY2025 annual result was $80.1 million, up 7.81% from the prior year.
• Other Non-Current Assets came in at $81.3 million for Q1 2026 at West Pharmaceutical Services, up from $80.1 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $81.3 million in Q1 2026 to a low of $1.2 million in Q3 2022.
• The 5-year median for Other Non-Current Assets is $49.4 million (2022), against an average of $50.4 million.
• Across the five-year window, Other Non-Current Assets tumbled 92.94% in 2022 and jumped 3133.33% in 2023, its largest moves.
• West Pharmaceutical Services' Other Non-Current Assets stood at $38.4 million in 2022, then plunged by 44.53% to $21.3 million in 2023, then surged by 248.83% to $74.3 million in 2024, then grew by 7.81% to $80.1 million in 2025, then rose by 1.5% to $81.3 million in 2026.
• The last three Other Non-Current Assets figures came in at $81.3 million (Q1 2026), $80.1 million (Q4 2025), and $75.8 million (Q3 2025), per Business Quant data.